- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 25
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 18 more
Location Directory
Clinical trials in Los Angeles, California
This page shows live ClinicalTrials.gov search results for Los Angeles, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
4646
Shown on this page
12
Current sort
Recently updated
Location scope
Los Angeles, CA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 493–504 of 4,646 matching trials in Los Angeles, CA.
Live ClinicalTrials.gov results.
Institutions in Los Angeles
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Surgery, Pain, Post Operative
- Interventions
- NSAID, Opioid, Acetaminophen, Ibuprofen
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 12 Years to 20 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 6 more
- Conditions
- Child Behavior, Child Behavior Problem, Child Behavior Disorders
- Interventions
- Self-Concept Reinforcement for Early School Readiness, Reach Out and Read
- Behavioral
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sickle Cell Disease
- Interventions
- CRISPR_SCD001
- Drug
- Lead sponsor
- Mark Walters, MD
- Other
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- Davis, California • Los Angeles, California • Oakland, California
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
- Interventions
- Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Irvine, California + 65 more
- Conditions
- Sarcoma, Ewing, Neoplasm Metastasis
- Interventions
- Abemaciclib, Irinotecan, Temozolomide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Indianapolis, Indiana + 2 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 46
- States / cities
- Goodyear, Arizona • Tucson, Arizona • Duarte, California + 37 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Setrusumab, Placebo
- Biological · Other
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 5 Years to 25 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Rochester, New York • Dallas, Texas
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 20
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 16 more
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography, Prostate Biopsy, Carcinoma of the Prostate
- Interventions
- 68Ga-PSMA-11
- Drug
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Boca Raton, Florida + 13 more
- Conditions
- Pulmonary Disease, Transcatheter Pulmonary Valve Replacement (TPVR), Tetralogy of Fallot, Congenital Heart Disease, Pulmonary Regurgitation
- Interventions
- Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more